Aimmune Therapeutics (AIMT) Misses Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Aimmune Therapeutics (AIMT) Misses Q4 EPS by 4c

Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights

February 28, 2019 4:01 PM EST

FDA decision on AR101 BLA filing acceptance expected by end of March Submission of AR101 marketing application in Europe on track for mid-2019 Initiation of AR201 phase 2 trial in egg allergy on track for mid-2019 Company began 2019 with approximately $340 million in cash and investments and potential access to an additional $130 million Webcast and conference call today at 5:00 p.m. ET

BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq:... More